Northrop Grumman arrives at its May 20 earnings report carrying a 20% one-month price decline — the deepest single-month loss among major US defense primes — and a Street still collectively pointing to targets well above the current price.
The most striking feature of this setup is how sharply options sentiment has shifted. The put/call ratio has dropped to 0.80, now running almost 1.6 standard deviations below its 20-day average of 0.91 — close to the lowest defensive reading in the past year. That is a meaningful reversal. Through late April, when the stock was selling off hardest, the PCR was above 1.0, signalling active hedging. In the two weeks since, call activity has reasserted itself, suggesting investors are positioning for a recovery rather than further downside — even after a week in which the stock shed another 1.6% to close at $540.69. The borrow market confirms the picture is not a short-led story: availability is extremely loose, cost to borrow holds near 0.42%, and short interest barely registers at 1.2% of the float — well below any threshold that would make squeeze dynamics relevant here.
The debate is entirely about whether the B-21 program and Sentinel restructuring risks are already priced. Bulls, who hold the majority of formal analyst coverage in a 10-buy, 10-hold split, point to Northrop's classified-work exposure (~34% of sales), a deep pipeline across missile defense and munitions, and the administration's stated intention to accelerate B-21 production. The consensus price target of $711.59 implies a return potential of roughly 32% from current levels. Morgan Stanley maintained Overweight after trimming to $745, and UBS and Citigroup both cut targets to the low-$740s while holding Buy — a cluster of firms trimming numbers but not conviction in the weeks around Q1 results. Bears counter that B-21 cost overruns and the Sentinel realignment remain live margin and free-cash-flow threats, with international revenue growth likely demanding higher capex and squeezing the FCF outlook. The forward P/E has compressed to 19x, down about 4.7 points over the past month — a re-rating that partially reflects those FCF concerns but hasn't yet convinced sellers to stop.
Historical reactions add another cautionary note. The most recent comparable print, in late April 2026, produced a one-day drop of 10.3% and a five-day decline of 12.0%. That was the worst single-session post-earnings move visible in the data. The prior event in April 2026 (an earlier announcement date) showed a milder 2.5% one-day loss. The pattern is not consistent, but the tail risk on the downside has clearly been large. Peer action this week is uniformly negative across the defense complex — LMT down 0.8%, RTX off 2.6%, HII down 3.2% — suggesting sector-level pressure rather than Northrop-specific stress.
Wednesday's print is less about whether Northrop can grow and more about whether management can credibly quantify the B-21 and Sentinel exposure in a way that bridges the roughly $170 gap between the current stock price and where the Street thinks it belongs.
See the live data behind this article on ORTEX.
Open NOC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
